KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.

Shin Nishio, Tadaaki Nishikawa, Masahiko Mori, Shoji Kamiura, Toshiyuki Sumi, Mayu Yunokawa, Yuichi Imai, Eiji Kondo, Kazuhiro Takehara, Hirokuni Takano, Wataru Kudaka, Nobuhiro Kado, Wataru Yamagami, Hidenori Kato, Koji Nishino, Tomoka Usami, Junzo Hamanishi, Masahiro Nii, Itsumi Takaya, Aikou Okamoto

J Gynecol Oncol 36(4) e118

PMID40590327
PMCIDPMC12226317
DOI10.3802/jgo.2025.36.e118
发表日期2025-07-01
入排依据:主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:森林图/亚组分析图;Fig. 3:非 KM 图;Fig. 4:森林图/亚组分析图。
摘要

摘要

OBJECTIVE: DUO-E/GOG-3041/ENGOT-EN10 (NCT04269200) demonstrated statistically significant and clinically meaningful progression-free survival (PFS) improvement with durvalumab plus carboplatin/paclitaxel, followed by durvalumab with or without olaparib, vs. carboplatin/paclitaxel alone (intention-to-treat [ITT] population) in patients with newly diagnosed advanced or recurrent endometrial cancer. We evaluated efficacy and safety in the Japan subset of DUO-E. METHODS: Patients with newly diagnosed International Federation of Gynecology and Obstetrics stage III/IV or recurrent endometrial cancer were randomized 1:1:1 to control arm (carboplatin/paclitaxel + durvalumab placebo [6 cycles] followed by durvalumab placebo + olaparib placebo), durvalumab arm (carboplatin/paclitaxel + durvalumab [1,120 mg every 3 weeks] [6 cycles] followed by durvalumab [1,500 mg every 4 weeks] + olaparib placebo), or durvalumab + olaparib arm (carboplatin/paclitaxel + durvalumab [6 cycles] followed by durvalumab + olaparib [300 mg twice a day]). Dual primary endpoints were investigator-assessed PFS for durvalumab and durvalumab + olaparib arms vs. control. This prespecified exploratory analysis evaluated PFS and safety in the Japan subset. RESULTS: In the Japan subset (n=88) PFS favored durvalumab (hazard ratio=0.61, 95% confidence interval [CI]=0.32-1.12) and durvalumab + olaparib (0.44, 95% CI=0.22-0.85) vs. control; median PFS was 9.9 and 15.1 vs. 9.5 months, and the 18-month PFS rate was 37.0% and 42.1% vs. 22.2%, respectively. The safety profile in the Japan subset was generally consistent with the full safety analysis set and the established profiles of the individual agents. CONCLUSION: Efficacy and safety in the Japan subset were generally consistent with outcomes in the DUO-E ITT population. This Japanese subset analysis of DUO-E supports carboplatin/paclitaxel + durvalumab followed by durvalumab with or without olaparib as new treatment options in patients with advanced or recurrent endometrial cancer and is the first to report on these regimens in Japanese patients alone.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Patient disposition for the DUO-E Japan subset. DCO, data cutoff.
非 KM Figure
Fig. 2Analyses of PFS according to RECIST version 1.1 in the subset of patients from Japan. Crosses indicate a censored observation. Patients without an event were censored at the latest evaluable RECIST assessment. CI, confidence interval; HR, hazard ratio; NR, not reached; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors.
非 KM Figure
Fig. 3Analyses of (A) ORR and (B) DoR in the subset of patients from Japan. CI, confidence interval; DoR, duration of response; IQR, interquartile range; NR, not reached; ORR, objective response rate; RECIST, Response Evaluation Criteria in Solid Tumors. * Data obtained until starting subsequent cancer therapy or up to RECIST progression or last RECIST assessment. † Odds of a response (complete or partial). Odds ratio >1 favors durvalumab or durvalumab + olaparib arm over control. ‡ Time from randomization to onset of response. § Time from first confirmed response until progression or censoring for progression-free survival.
非 KM Figure
Fig. 4Analyses of (A) TDT, (B) TFST, (C) PFS2 and (D) TSST in the subset of patients from Japan. Time to event rates were estimated by the Kaplan-Meier method. CI, confidence interval; HR, hazard ratio; NR, not reached; PFS2, time from randomization to second progression or death; TDT, time to treatment discontinuation or death; TFST, time to first subsequent therapy or death; TSST, time to second subsequent therapy or death. * CIs for medians were derived using the Brookmeyer–Crowley method. † HRs were estimated from an unstratified Cox proportional hazards model. CIs were calculated using a profile likelihood approach.
非 KM Figure